Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110502 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Wei Lin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong China. Hauptthemen laut MEDLINE: Synoviocytes, Arthritis, Experimental, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease causing joint dysfunction. As disease-modifying anti-rheumatic drugs (DMARDs) have poor efficacy in 20% to 25% of RA patients, additional novel RA medications are urgently needed. Schisandrin (SCH) has multiple therapeutic effects. However, whether SCH is effective against RA remains unknown. PURPOSE: To investigate how SCH affects the abnormal behaviours of RA fibroblast-like synoviocytes (FLSs) and further elucidate the underlying mechanism of SCH in RA FLSs and collagen-induced arthritis (CIA) mice. METHODS: Cell Counting Kit-8 (CCK8) assays were used to characterize cell viability. EdU assays were performed to assess cell proliferation. Annexin V-APC/PI assays were used to determine apoptosis. Transwell chamber assays were used to measure cell migration and invasion in vitro. RT-qPCR was used to assess proinflammatory cytokine and MMP mRNA expression. Western blotting was used to detect protein expression. RNA sequencing was performed to explore the potential downstream targets of SCH. CIA model mice were used to assess the treatment efficacy of SCH in vivo. RESULTS: Treatments with SCH (50, 100, and 200 μΜ) inhibited RA FLSs proliferation, migration, invasion, and TNF-α-induced IL-6, IL-8, and CCL2 expression in a dose-dependent manner but did not affect RA FLSs viability or apoptosis. RNA sequencing and Reactome enrichment analysis indicated that SREBF1 might be the downstream target in SCH treatment. Furthermore, knockdown of SREBF1 exerted effects similar to those of SCH in inhibiting RA FLSs proliferation, migration, invasion, and TNF-α-induced expression of IL-6, IL-8, and CCL2. Both SCH treatment and SREBF1 knockdown decreased activation of the PI3K/AKT and NF-κB signalling pathways. Moreover, SCH ameliorated joint inflammation and cartilage and bone destruction in CIA model mice. CONCLUSION: SCH controls the pathogenic behaviours of RA FLSs by targeting SREBF1-mediated activation of the PI3K/AKT and NF-κB signalling pathways. Our data suggest that SCH inhibits FLS-mediated synovial inflammation and joint damage and that SCH might have therapeutic potential for RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong China.
- Department of Rheumatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong China.
- Department of Rheumatology, The First People's Hospital of Foshan, Foshan, Guangdong China.
- Department of Rheumatology, The First People's Hospital of Foshan, Foshan, Guangdong China. Electronic address: 13929981788@139.com.
- Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong China. Electronic address: xuhanshi@mail.sysu.edu.cn.
- Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong China. Electronic address: lliuq@mail.sysu.edu.cn.
Zitieren
APA
Lin, W., Liu, Y., Zhang, S., Xu, S., Qiu, Q., Wang, C., Liu, D., Shen, C., Xu, M., Shi, M., Xiao, Y., Chen, G., Xu, H., & Liang, L. (2023). Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110502
Vancouver
Lin W, Liu Y, Zhang S, Xu S, Qiu Q, Wang C, et al. Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110502
BibTeX
@article{Lin2023,
author = {Lin, Wei and Liu, Yingli and Zhang, Shuoyang and Xu, Siqi and Qiu, Qian and Wang, Cuicui and Liu, Di and Shen, Chuyu and Xu, Meilin and Shi, Maohua and Xiao, Youjun and Chen, Guoqiang and Xu, Hanshi and Liang, Liuqin},
title = {Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110502}
}
EUVIMED